Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.

Meliani A, Boisgerault F, Fitzpatrick Z, Marmier S, Leborgne C, Collaud F, Simon Sola M, Charles S, Ronzitti G, Vignaud A, van Wittenberghe L, Marolleau B, Jouen F, Tan S, Boyer O, Christophe O, Brisson AR, Maguire CA, Mingozzi F.

Blood Adv. 2017 Oct 16;1(23):2019-2031. doi: 10.1182/bloodadvances.2017010181. eCollection 2017 Oct 24.

2.

Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.

Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, Collaud F, Simon-Sola M, Charles S, Hardet R, Leborgne C, Meliani A, Cohen-Tannoudji M, Astord S, Gjata B, Sellier P, van Wittenberghe L, Vignaud A, Boisgerault F, Barkats M, Laforet P, Kay MA, Koeberl DD, Ronzitti G, Mingozzi F.

Sci Transl Med. 2017 Nov 29;9(418). pii: eaam6375. doi: 10.1126/scitranslmed.aam6375.

3.

Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.

Hösel M, Huber A, Bohlen S, Lucifora J, Ronzitti G, Puzzo F, Boisgerault F, Hacker UT, Kwanten WJ, Klöting N, Blüher M, Gluschko A, Schramm M, Utermöhlen O, Bloch W, Mingozzi F, Krut O, Büning H.

Hepatology. 2017 Jul;66(1):252-265. doi: 10.1002/hep.29176. Epub 2017 May 29.

4.
5.

Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors.

Ferrand M, Da Rocha S, Corre G, Galy A, Boisgerault F.

Mol Ther. 2015 Jun;23(6):1022-1033. doi: 10.1038/mt.2015.59. Epub 2015 Apr 16.

6.

Hypoxic culture conditions enhance the generation of regulatory T cells.

Neildez-Nguyen TMA, Bigot J, Da Rocha S, Corre G, Boisgerault F, Paldi A, Galy A.

Immunology. 2015 Mar;144(3):431-443. doi: 10.1111/imm.12388.

7.

A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer.

Ferrand M, Galy A, Boisgerault F.

Gene Ther. 2014 Sep;21(9):828-39. doi: 10.1038/gt.2014.61. Epub 2014 Jul 17.

8.

Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer.

Boisgerault F, Gross DA, Ferrand M, Poupiot J, Darocha S, Richard I, Galy A.

Hum Gene Ther. 2013 Apr;24(4):393-405. doi: 10.1089/hum.2012.208.

PMID:
23427817
9.

MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV.

Sudres M, Ciré S, Vasseur V, Brault L, Da Rocha S, Boisgérault F, Le Bec C, Gross DA, Blouin V, Ryffel B, Galy A.

Mol Ther. 2012 Aug;20(8):1571-81. doi: 10.1038/mt.2012.101. Epub 2012 May 29.

10.

Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants.

Boisgérault F, Liu Y, Anosova N, Dana R, Benichou G.

Transplantation. 2009 Jan 15;87(1):16-23. doi: 10.1097/TP.0b013e318191b38b.

11.

TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help.

Hervas-Stubbs S, Olivier A, Boisgerault F, Thieblemont N, Leclerc C.

Blood. 2007 Jun 15;109(12):5318-26. Epub 2007 Mar 5.

12.

Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal.

Boisgérault F, Rueda P, Sun CM, Hervas-Stubbs S, Rojas M, Leclerc C.

J Immunol. 2005 Mar 15;174(6):3432-9.

13.

Partial activation of neonatal CD11c+ dendritic cells and induction of adult-like CD8+ cytotoxic T cell responses by synthetic microspheres.

Regner M, Martinez X, Belnoue E, Sun CM, Boisgerault F, Lambert PH, Leclerc C, Siegrist CA.

J Immunol. 2004 Aug 15;173(4):2669-74.

14.

Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.

Kim YM, Mapara MY, Down JD, Johnson KW, Boisgerault F, Akiyama Y, Benichou G, Pelot M, Zhao G, Sykes M.

Blood. 2004 Jan 15;103(2):732-9. Epub 2003 Sep 25.

15.

Virus-like particles: a new family of delivery systems.

Boisgérault F, Morón G, Leclerc C.

Expert Rev Vaccines. 2002 Jun;1(1):101-9. Review.

PMID:
12908517
16.

Mechanisms of immunotherapeutic intervention by anti-CD154 (CD40L) antibody in high-risk corneal transplantation.

Qian Y, Hamrah P, Boisgerault F, Yamagami S, Vora S, Benichou G, Dana MR.

J Interferon Cytokine Res. 2002 Dec;22(12):1217-25.

PMID:
12581495
17.

The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant.

Illigens BM, Yamada A, Fedoseyeva EV, Anosova N, Boisgerault F, Valujskikh A, Heeger PS, Sayegh MH, Boehm B, Benichou G.

Hum Immunol. 2002 Oct;63(10):912-25.

PMID:
12368044
18.

Antigenicity and immunogenicity of allogeneic retinal transplants.

Anosova NG, Illigens B, Boisgérault F, Fedoseyeva EV, Young MJ, Benichou G.

J Clin Invest. 2001 Oct;108(8):1175-83.

19.

[Subtypes of the HLA-B27 molecule and association with spondylarthropathies].

Toubert A, Tieng V, Boisgérault F, Dulphy N, Tamouza R, Charron D.

Ann Med Interne (Paris). 1998 Apr;149(3):145-8. French.

PMID:
11490536
20.

Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation.

Boisgérault F, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G.

J Immunol. 2001 Aug 15;167(4):1891-9.

21.

Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants.

Qian Y, Boisgerault F, Benichou G, Dana MR.

Invest Ophthalmol Vis Sci. 2001 Apr;42(5):987-94.

PMID:
11274076
22.

Induction of T-cell response to cryptic MHC determinants during allograft rejection.

Boisgérault F, Anosova NG, Tam RC, Illigens BM, Fedoseyeva EV, Benichou G.

Hum Immunol. 2000 Dec;61(12):1352-62.

PMID:
11163093
23.

Analysis of T-cell response using altered peptide ligands.

Boisgérault F, Anosova N, Fedoseyeva EV, Tam RC, Benichou G.

Methods Mol Biol. 2001;156:211-8. No abstract available.

PMID:
11068762
24.

CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice.

Fedoseyeva EV, Boisgérault F, Anosova NG, Wollish WS, Arlotta P, Jensen PE, Ono SJ, Benichou G.

J Immunol. 2000 Jun 1;164(11):5641-51.

25.

Naturally processed peptides from HLA-DQ7 (alpha1*0501-beta1*0301): influence of both alpha and beta chain polymorphism in the HLA-DQ peptide binding specificity.

Khalil-Daher I, Boisgérault F, Feugeas JP, Tieng V, Toubert A, Charron D.

Eur J Immunol. 1998 Nov;28(11):3840-9.

26.

Alteration of HLA-B27 peptide presentation after infection of transfected murine L cells by Shigella flexneri.

Boisgérault F, Mounier J, Tieng V, Stolzenberg MC, Khalil-Daher I, Schmid M, Sansonetti P, Charron D, Toubert A.

Infect Immun. 1998 Sep;66(9):4484-90.

27.

Protein transport and processing by human HT29-19A intestinal cells: effect of interferon gamma.

Terpend K, Boisgerault F, Blaton MA, Desjeux JF, Heyman M.

Gut. 1998 Apr;42(4):538-45.

28.

HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes.

Tieng V, Dulphy N, Boisgérault F, Tamouza R, Charron D, Toubert A.

Immunogenetics. 1997;47(1):103-5. No abstract available.

PMID:
9382929
29.

Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies.

Boisgérault F, Tieng V, Stolzenberg MC, Dulphy N, Khalil I, Tamouza R, Charron D, Toubert A.

J Clin Invest. 1996 Dec 15;98(12):2764-70.

30.

Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy.

Boisgerault F, Khalil I, Tieng V, Connan F, Tabary T, Cohen JH, Choppin J, Charron D, Toubert A.

Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3466-70.

Supplemental Content

Loading ...
Support Center